Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 26, 2004

View Archived Issues

First safety review completed for phase II study of HepeX-B

Target enrollment reached in ARISE study of AGI-1067 for atherosclerosis

MedImmune and Medarex to develop antibodies for autoimmune diseases

Cenomed licenses analogues for cognitive disorders from Medical College of Georgia

GSK profiles CNS pipeline

Enrollment temporarily suspended in phase III surgical study of Inactine system

Phase I data supports the use of IMOxine in cancer immunotherapy

GlaxoSmithKline to develop NS-2359 for depression

Trigen and Eurand to develop controlled-release TGN-167

Japanese launch of Valixa for CMV retinitis

New dosage forms of AG-013736

Coumarinolignoid composition for use as hepatoprotective agent described in patent

Agent for fungal infections and cancer isolated from lichen

Scientists at Aventis claim new azetidinone and its use as a treatment for hyperlipidemia

Novel cathepsin K inhibitors in early development at Sankyo

New insulin secretagogues claimed in Bayer patent

Indian researchers isolate antibacterial agent from Cymbopogon flexuosus

Novel agent by Microbia shows antinociceptive effects in animal models of visceral pain

Neuronal Shp2 tyrosine phosphatase targeted for the treatment of obesity

Chondroprotective effects of glucosamine analogue against osteoarthritis

Bifunctional small molecules inhibit Abeta aggregation

Ferumoxtran-10 improves MRI detection of metastatic nodes in bladder cancer

Antihypertensive effects found for rosiglitazone in diabetics with hypertension

Merimepodib increases virological response to interferon plus ribavirin therapy in hepatitis C

HepeX-B reduces viral load of patients with chronic HBV infection

Two-year data on the effects of statins on glycemic control

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 13, 2026.
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...
Muscarinic M4 receptor positive allosteric modulators described in Neurosterix patent
BioWorld Science
Neurosterix Pharma Sarl has divulged 3-cyclopropylpyrazole derivatives acting as muscarinic M4 receptor positive allosteric modulators. They are reported to be...